GFM
NMRA icon

GF Fund Management’s Neumora Therapeutics NMRA Stock Holding History

GF Fund Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.9K Sell
3,471
-266
-7% -$506 ﹤0.01% 565
2026
Q1 		$7.29K Buy
3,737
+455
+14% +$1.18K ﹤0.01% 584
2025
Q4 		$5.88K Sell
3,282
-202
-6% -$442 ﹤0.01% 617
2025
Q3 		$6.34K Sell
3,484
-399
-10% -$645 ﹤0.01% 592
2025
Q2 		$2.85K Hold
3,883
– – ﹤0.01% 645
2025
Q1 		$3.88K Buy
3,883
+491
+14% +$841 ﹤0.01% 631
2024
Q4 		$36K Buy
+3,392
New +$40.7K ﹤0.01% 420

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GF Fund Management's NMRA Position: Q2 2026 in Review

GF Fund Management reduced its Neumora Therapeutics (NMRA) stake by 7.1% in Q2 2026, selling an estimated $506 and leaving 3,471 shares worth $5.9K. The position accounts for ﹤0.01% of the portfolio, ranked #565.

GF Fund Management first reported a position in NMRA in Q4 2024 and has held it in 7 quarters since. The position peaked at $36K in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • GF Fund Management held 3,471 shares of Neumora Therapeutics worth $5.9K as of Q2 2026.
  • GF Fund Management sold 266 Neumora Therapeutics shares in Q2 2026, an estimated $506.
  • Neumora Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #565 holding.
  • GF Fund Management first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Neumora Therapeutics position peaked at $36K in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.